Literature DB >> 4074375

Kinetics of the reaction of cis-platinum compounds with DNA in vitro.

J L Butour, A M Mazard, J P Macquet.   

Abstract

The kinetics of the reaction of a series of cis-platinum(II) compounds with DNA in vitro has been studied using their ability to disturb the secondary structure of the macromolecule. The complexation modifies the stacking of the base pairs and causes an inhibition of the intercalation of ethidium bromide which is correlated with the number of platinum atoms bound per nucleotide. The compounds fall into three groups which react in a few minutes, in a few hours or in several days. The inhibition of the complexation by chloride and carboxylato ions indicates that the interaction occurs through hydrolysed species and that hydrolysis is the rate limiting step. In addition the results indicate that the carboxylato entities are able to react with DNA in vitro without enzymatic activation and that there is no correlation between the antitumoral activity of these compounds against L1210 Leukemia cells and their in vitro reactivity towards DNA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074375     DOI: 10.1016/0006-291x(85)91882-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.

Authors:  C L King; S Ramachandran; S G Chaney; L Collins; J A Swenberg; K E DeKrafft; W Lin; L Cicurel; M Barbier
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

Review 2.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 3.  Progress in colorectal cancer chemotherapy: how far have we come, how far to go?

Authors:  M E Royce; P M Hoff; R Pazdur
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 4.  Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexed.

Authors:  M E Royce; P M Hoff; R Padzur
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

5.  Pharmacokinetics of oxaliplatin in humans.

Authors:  H Ehrsson; I Wallin; J Yachnin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 6.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

7.  Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex.

Authors:  Elin Jerremalm; Mikael Hedeland; Inger Wallin; Ulf Bondesson; Hans Ehrsson
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

8.  Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.

Authors:  Zhi-Yu Xiao; Wei Wu; Navada Eagleton; Huan-Qing Chen; Jing Shao; Hong Teng; Tian-Hao Liu; Zhi-Min Jiang; He-Rui Yao
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.